114 related articles for article (PubMed ID: 15123527)
1. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM
Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527
[TBL] [Abstract][Full Text] [Related]
2. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement.
Lewandowski KC; Murray RD; Drzewoski J; O'Callaghan CJ; Czupryniak L; Hillhouse EW; Shalet SM; Randeva HS
Mol Genet Metab; 2003 Nov; 80(3):330-7. PubMed ID: 14680980
[TBL] [Abstract][Full Text] [Related]
3. IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth.
Yildiz B; Kural N; Colak O; Ak I; Akcar N
Clin Physiol Funct Imaging; 2008 Mar; 28(2):107-12. PubMed ID: 18093232
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease.
Lee SD; Chen LM; Kuo WW; Shu WT; Kuo WH; Huang EJ; Tsai CC; Li PC; Liu JY; Chen TH; Huang CY
Clin Chim Acta; 2006 May; 367(1-2):62-8. PubMed ID: 16406300
[TBL] [Abstract][Full Text] [Related]
5. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults.
Murray RD; Randeva HS; Lewandowski KC; Komorowski J; Lawrance JA; Adams JE; Shalet SM
Growth Horm IGF Res; 2011 Apr; 21(2):96-101. PubMed ID: 21450501
[TBL] [Abstract][Full Text] [Related]
6. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
7. New insights into molecular mechanisms of diffuse coronary ectasiae: a possible role for VEGF.
Savino M; Parisi Q; Biondi-Zoccai GG; Pristipino C; Cianflone D; Crea F
Int J Cardiol; 2006 Jan; 106(3):307-12. PubMed ID: 16337037
[TBL] [Abstract][Full Text] [Related]
8. Plasma matrix metalloproteinase-9 levels and blood pressure in short children born small for gestational age and effects of growth hormone treatment.
Willemsen RH; van Dijk M; de Kort SW; van Toorenenbergen AW; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Aug; 69(2):264-8. PubMed ID: 18284641
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.
Gentilini F; Calzolari C; Turba ME; Agnoli C; Fava D; Forni M; Bergamini PF
Leuk Res; 2005 Nov; 29(11):1263-9. PubMed ID: 15893373
[TBL] [Abstract][Full Text] [Related]
10. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
Esposito V; Di Biase S; Lettiero T; Labella D; Simeone R; Salerno M
Clin Endocrinol (Oxf); 2004 Nov; 61(5):607-11. PubMed ID: 15521964
[TBL] [Abstract][Full Text] [Related]
11. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.
Abd El Aal DE; Mohamed SA; Amine AF; Meki AR
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):219-24. PubMed ID: 15653207
[TBL] [Abstract][Full Text] [Related]
13. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
15. Growth factors decrease in subjects with mild to moderate Alzheimer's disease (AD): potential correction with dehydroepiandrosterone-sulphate (DHEAS).
Luppi C; Fioravanti M; Bertolini B; Inguscio M; Grugnetti A; Guerriero F; Rovelli C; Cantoni F; Guagnano P; Marazzi E; Rolfo E; Ghianda D; Levante D; Guerrini C; Bonacasa R; Solerte SB
Arch Gerontol Geriatr; 2009; 49 Suppl 1():173-84. PubMed ID: 19836631
[TBL] [Abstract][Full Text] [Related]
16. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
[TBL] [Abstract][Full Text] [Related]
17. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Paisley AN; O'Callaghan CJ; Lewandowski KC; Parkinson C; Roberts ME; Drake WM; Monson JP; Trainer PJ; Randeva HS
J Clin Endocrinol Metab; 2006 Nov; 91(11):4635-40. PubMed ID: 16926249
[TBL] [Abstract][Full Text] [Related]
18. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset.
Columb B; Smethurst LE; Mukherjee A; Jostel A; Shalet SM; Murray RD
Clin Endocrinol (Oxf); 2009 Feb; 70(2):281-6. PubMed ID: 18702681
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy].
Peczyńska J; Urban M; Urban B; Głowińska B; Florys B
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(1):41-8. PubMed ID: 15355738
[TBL] [Abstract][Full Text] [Related]
20. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
